<p>在最新的季度中，7 位分析師對貝克頓·迪金森（NYSE: BDX）提供了評級，展現出看漲和看跌的不同觀點。</p>
<p>下表提供了他們最近評級的快照，展示了過去 30 天情緒的演變，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>在對 12 個月價格目標的評估中，分析師為貝克頓·迪金森提供了見解，呈現出 205.57 美元的平均目標，最高預估為 215.00 美元，最低預估為 190.00 美元。當前平均目標較之前的 200.00 美元上升了 2.78%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769626872_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769626872_0.png"/></p>
<h2>分析師評級調查：詳盡研究</h2>
<p>通過最近的分析師行動，分析了金融專家對貝克頓·迪金森的看法。以下摘要呈現了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>上調</td>
<td>中性</td>
<td>$205.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>上調</td>
<td>買入</td>
<td>$215.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>上調</td>
<td>中性</td>
<td>$207.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>上調</td>
<td>行業表現</td>
<td>$210.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>上調</td>
<td>超配</td>
<td>$210.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>下調</td>
<td>行業表現</td>
<td>$202.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>下調</td>
<td>中性</td>
<td>$190.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師根據市場條件和公司表現調整他們的建議。無論是 “維持”、“上調” 還是 “下調”，都反映了他們對貝克頓·迪金森近期發展的反應。這些信息提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 分析師提供全面分析，給出定性評估，範圍從 “跑贏大盤” 到 “跑輸大盤”。這些評級反映了對貝克頓·迪金森相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 分析師提供對貝克頓·迪金森股票未來價值的估計。這種比較揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
<p>為了全面瞭解貝克頓·迪金森的市場表現，請探索這些分析師評估以及重要的財務指標。保持信息靈通，利用我們的評級表做出明智的決策。</p>
<p>隨時瞭解貝克頓·迪金森的分析師評級。</p>
<h2>深入瞭解貝克頓·迪金森的背景</h2>
<p>貝克頓·迪金森是全球最大的醫療外科產品製造和分銷商，產品包括針頭、注射器和鋭器處置單元。該公司還製造預填充設備、診斷儀器和試劑，以及流式細胞儀和細胞成像系統。BD Medical 幾乎佔總業務的一半，而 BD Life Sciences（2024 年收入的 26%）和 BD Interventional（25%）佔其餘部分。國際收入佔公司業務的 43%。</p>
<h3>分析貝克頓·迪金森的財務表現</h3>
<p><strong>市值分析：</strong> 公司的市值高於行業平均水平，表明其相對於同行規模較大。這可能暗示着更高的投資者信心和市場認可度。</p>
<p><strong>收入增長：</strong> 貝克頓·迪金森在過去 3 個月的收入增長顯著。截至 2025 年 9 月 30 日，公司實現了約 <strong>8.35%</strong> 的收入增長率。這表明公司的頂線收益有了顯著增加。與醫療保健行業的其他公司相比，該公司面臨挑戰，增長率低於同行的平均水平。</p>
<p><strong>淨利潤率：</strong> 公司的淨利潤率表現突出，超過行業平均水平。憑藉 <strong>8.37%</strong> 的淨利潤率，公司展現出強勁的盈利能力和有效的成本控制。</p>
<p><strong>股本回報率（ROE）：</strong> 貝克頓·迪金森的 ROE 低於行業平均水平，表明在最大化股本回報方面面臨挑戰。ROE 為 <strong>1.94%</strong>，公司可能在實現最佳財務表現方面面臨困難。</p>
<p><strong>資產回報率（ROA）：</strong> 貝克頓·迪金森的 ROA 低於行業平均水平，表明在最大化資產回報方面面臨挑戰。ROA 為 <strong>0.89%</strong>，公司可能在實現最佳財務表現方面面臨困難。</p>
<p><strong>債務管理：</strong> 貝克頓·迪金森的債務與股本比率為 <strong>0.76</strong>，低於行業平均水平，反映出對債務融資的依賴較低，財務策略更為保守。</p>
<h2>分析師評級的基礎知識</h2>
<p>在銀行和金融系統領域，分析師專注於特定股票或定義的行業進行報告。他們的工作包括參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈股票的 “分析師評級”。分析師通常每季度評估和評級每隻股票一次。</p>
<p>一些分析師發佈他們對增長預期、收益和收入等指標的預測，以便為他們的評級提供額外的指導。在使用分析師評級時，重要的是要記住，股票和行業分析師也是人，他們只是向投資者提供他們的意見。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>

美國醫藥設備 ETF - iShares

碧迪醫療

標普健康醫療設備 ETF - SPDR

<p>在最新的季度中，7 位分析師對碧迪醫療（NYSE:BDX）給出了混合評級，12 個月的平均目標價為 205.57 美元，較之前的目標價上漲了 2.78%。分析師根據市場情況調整了他們的評級，其中皮博格·桑德勒（Piper Sandler）和斯蒂費爾（Stifel）等公司的變化尤為顯著。作為領先的醫療產品製造商，碧迪醫療顯示出 8.35% 的強勁收入增長，但在股本回報率和資產回報率方面面臨挑戰。該公司的債務與股本比率低於行業平均水平，表明其採取了保守的財務策略</p>

<p>In the latest quarter, 7 analysts provided ratings for Becton Dickinson (NYSE: BDX), showcasing a mix of bullish and bearish perspectives.</p>
<div class="lb-trans"><p>在最新的季度中，7 位分析師對貝克頓·迪金森（NYSE: BDX）提供了評級，展現出看漲和看跌的不同觀點。</p>
</div><p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他們最近評級的快照，展示了過去 30 天情緒的演變，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>In the assessment of 12-month price targets, analysts unveil insights for Becton Dickinson, presenting an average target of $205.57, a high estimate of $215.00, and a low estimate of $190.00. Witnessing a positive shift, the current average has risen by 2.78% from the previous average price target of $200.00.</p>
<div class="lb-trans"><p>在對 12 個月價格目標的評估中，分析師為貝克頓·迪金森提供了見解，呈現出 205.57 美元的平均目標，最高預估為 215.00 美元，最低預估為 190.00 美元。當前平均目標較之前的 200.00 美元上升了 2.78%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769626872_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769626872_0.png"/></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<div class="lb-trans"><h2>分析師評級調查：詳盡研究</h2>
</div><p>The perception of Becton Dickinson by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過最近的分析師行動，分析了金融專家對貝克頓·迪金森的看法。以下摘要呈現了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$207.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$210.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$202.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>上調</td>
<td>中性</td>
<td>$205.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>上調</td>
<td>買入</td>
<td>$215.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>上調</td>
<td>中性</td>
<td>$207.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>上調</td>
<td>行業表現</td>
<td>$210.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>上調</td>
<td>超配</td>
<td>$210.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>下調</td>
<td>行業表現</td>
<td>$202.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>下調</td>
<td>中性</td>
<td>$190.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Becton Dickinson. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Becton Dickinson compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Becton Dickinson's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師根據市場條件和公司表現調整他們的建議。無論是 “維持”、“上調” 還是 “下調”，都反映了他們對貝克頓·迪金森近期發展的反應。這些信息提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 分析師提供全面分析，給出定性評估，範圍從 “跑贏大盤” 到 “跑輸大盤”。這些評級反映了對貝克頓·迪金森相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 分析師提供對貝克頓·迪金森股票未來價值的估計。這種比較揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
</div><p>To gain a panoramic view of Becton Dickinson's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<div class="lb-trans"><p>為了全面瞭解貝克頓·迪金森的市場表現，請探索這些分析師評估以及重要的財務指標。保持信息靈通，利用我們的評級表做出明智的決策。</p>
</div><p>Stay up to date on Becton Dickinson analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解貝克頓·迪金森的分析師評級。</p>
</div><h2>Delving into Becton Dickinson's Background</h2>
<div class="lb-trans"><h2>深入瞭解貝克頓·迪金森的背景</h2>
</div><p>Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.</p>
<div class="lb-trans"><p>貝克頓·迪金森是全球最大的醫療外科產品製造和分銷商，產品包括針頭、注射器和鋭器處置單元。該公司還製造預填充設備、診斷儀器和試劑，以及流式細胞儀和細胞成像系統。BD Medical 幾乎佔總業務的一半，而 BD Life Sciences（2024 年收入的 26%）和 BD Interventional（25%）佔其餘部分。國際收入佔公司業務的 43%。</p>
</div><h3>Breaking Down Becton Dickinson's Financial Performance</h3>
<div class="lb-trans"><h3>分析貝克頓·迪金森的財務表現</h3>
</div><p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值高於行業平均水平，表明其相對於同行規模較大。這可能暗示着更高的投資者信心和市場認可度。</p>
</div><p><strong>Revenue Growth:</strong> Becton Dickinson's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately <strong>8.35%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> 貝克頓·迪金森在過去 3 個月的收入增長顯著。截至 2025 年 9 月 30 日，公司實現了約 <strong>8.35%</strong> 的收入增長率。這表明公司的頂線收益有了顯著增加。與醫療保健行業的其他公司相比，該公司面臨挑戰，增長率低於同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>8.37%,</strong> the company showcases strong profitability and effective cost control.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> 公司的淨利潤率表現突出，超過行業平均水平。憑藉 <strong>8.37%</strong> 的淨利潤率，公司展現出強勁的盈利能力和有效的成本控制。</p>
</div><p><strong>Return on Equity (ROE):</strong> Becton Dickinson's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>1.94%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> 貝克頓·迪金森的 ROE 低於行業平均水平，表明在最大化股本回報方面面臨挑戰。ROE 為 <strong>1.94%</strong>，公司可能在實現最佳財務表現方面面臨困難。</p>
</div><p><strong>Return on Assets (ROA):</strong> Becton Dickinson's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.89%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> 貝克頓·迪金森的 ROA 低於行業平均水平，表明在最大化資產回報方面面臨挑戰。ROA 為 <strong>0.89%</strong>，公司可能在實現最佳財務表現方面面臨困難。</p>
</div><p><strong>Debt Management:</strong> Becton Dickinson's debt-to-equity ratio is below the industry average at <strong>0.76</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> 貝克頓·迪金森的債務與股本比率為 <strong>0.76</strong>，低於行業平均水平，反映出對債務融資的依賴較低，財務策略更為保守。</p>
</div><h2>The Basics of Analyst Ratings</h2>
<div class="lb-trans"><h2>分析師評級的基礎知識</h2>
</div><p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish &#34;analyst ratings&#34; for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>在銀行和金融系統領域，分析師專注於特定股票或定義的行業進行報告。他們的工作包括參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈股票的 “分析師評級”。分析師通常每季度評估和評級每隻股票一次。</p>
</div><p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<div class="lb-trans"><p>一些分析師發佈他們對增長預期、收益和收入等指標的預測，以便為他們的評級提供額外的指導。在使用分析師評級時，重要的是要記住，股票和行業分析師也是人，他們只是向投資者提供他們的意見。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>
</div>

分析師的判決：7 位專家眼中的碧迪醫療